A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.


Updates from The Motley Fool

Latest updates on Geron from Fool.com.  The Fool has written over 200 articles on Geron.
4 Top Stocks Under $5

Image source: Getty Images. Even though there are more than 7,000 equities listed on U.S. stock e...

3 Top Stocks Under $5

Image source: Geralt from Pixabay Very few companies want to see their stock trade below $5 per s...

3 Small-Cap Stocks to Buy in July

Image source: Getty Images. Summer is officially in full swing, and July is almost upon us. But b...

3 Biotech Stocks to Buy on Sale

Image Source TBIT via pixabay The broad S&P 500 has rallied over the last few weeks, and it has...

3 Stocks That Could Make You Rich

Image source: The Motley Fool. For any investor looking to put money to work in the stock market ...



Stock Performance

View Interactive GERN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Geron.
Current Price: $2.08
Prev Close: $2.01
Open: $2.05
Bid: $2.04
Ask: $2.13
Day's Range: $2.02 - $2.13
52wk Range: $1.81 - $5.29
Volume: 1,477,126
Avg Vol 1,314,453
Market Cap: $329M
P/E (ttm): -11.17
EPS (ttm): ($0.18)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Geron.
CAPS Rating 2 out of 5
 
645 Outperform
63 Underperform
CAPS All Stars
 
81 Outperform
18 Underperform

How do you think Geron will perform against the market?



You pick for Geron is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John A. Scarlett, CEO

100% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Geron.

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers